Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study)
| Autor: | Bernardo Cortese, Akihito Tanaka, Azeem Latib, Renatomaria Bianchi, Elisabetta Moscarella, Maria Carmen De Angelis, Sebastian Coscarelli, Paolo Calabrò, Giulietta Grigis, Maurizio Tespili, Dario Buccheri, Antonio Colombo, Pedro Silva Orrego, Davide Piraino, Alfonso Ielasi, Attilio Varricchio |
|---|---|
| Přispěvatelé: | Moscarella, Elisabetta, Tanaka, Akihito, Ielasi, Alfonso, Cortese, Bernardo, Coscarelli, Sebastian, De Angelis, Maria Carmen, Piraino, Davide, Latib, Azeem, Grigis, Giulietta, Bianchi, Renatomaria, Buccheri, Dario, Calabrò, Paolo, Tespili, Maurizio, Silva Orrego, Pedro, Colombo, Antonio, Varricchio, Attilio |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.medical_treatment Urology 030204 cardiovascular system & hematology Prosthesis Design Balloon Risk Assessment Cardiac Catheters Coronary Restenosis 03 medical and health sciences 0302 clinical medicine Coated Materials Biocompatible Restenosis Risk Factors Absorbable Implants medicine Humans Radiology Nuclear Medicine and imaging Everolimus 030212 general & internal medicine Angioplasty Balloon Coronary Propensity Score Aged Retrospective Studies Bioresorbable vascular scaffold in stent restenosi business.industry Incidence (epidemiology) percutaneous coronary intervention Stent Percutaneous coronary intervention Cardiovascular Agents Drug-Eluting Stents General Medicine Middle Aged medicine.disease Treatment Outcome Italy Drug-eluting stent Propensity score matching Female bioresorbable vascular scaffold drug eluting balloon Cardiology and Cardiovascular Medicine business drug eluting stent |
| Popis: | Objectives to compare the 1-year outcome between bioresorbable vascular scaffold (BVS), everolimus-eluting stent (EES), and drug-eluting balloon (DEB) for in-stent restenosis (ISR) treatment. Background BVS has been proposed as alternative for ISR treatment. To date a direct comparison between BVS and DES or DEB for ISR treatment is lacking. Methods We retrospectively analyzed all ISR lesions treated with BVS, DEB, and EES from January 2012 to December 2014. A total of 548 lesions (498 patients) were included. By applying two propensity-score matching, 93 lesions treated with BVS were compared with 93 lesions treated with DEB, and 100 lesions treated with BVS were compared to 100 lesions treated with EES. Results At 1-year follow-up the incidence of device-oriented cardiovascular events (DOCE) and its components did not significantly differ between BVS and DEB (DOCE: 10.9 vs. 11.8%, HR, 0.91; 95% CI, 0.33-2.52; P = 0.86; Cardiac death: 2.2 vs. 1.2%, HR, 1.74, 95% CI 0.16-18.80, P = 0.65; ID-TLR: 8.9 vs. 10.7%, HR, 0.81, 95% CI 0.27-2.48, P = 0.71; TV-MI: 3.3 vs. 1.2%, HR, 2.39, 95% CI 0.27-21.32, P = 0.43) and BVS vs. EES (DOCE: 10.1 vs. 5.2% HR, 1.81, 95% CI, 0.63-5.25; P = 0.27; Cardiac death: 3.0 vs. 1.1%; HR, 2.83, 95% CI 0.29-27.4, P = 0.37; ID-TLR: 7.2 vs. 4.2%, HR, 1.57, 95% CI 0.47-5.23, P = 0.46; TV-MI: 3.1 vs. 0%). Conclusion At 1-year follow-up the use of BVS as ISR treatment is associated with a higher, even if not significant, DOCE rate compared with EES while a similar rate compared to DEB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|